Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of N02RS1 600mg and 1,200mg per day in Patients With acute and acute exacerbation of chronic bronchitis for 7 days.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PharmaKing

Criteria

Inclusion Criteria:

• Patients over 18, under 75 years of age

• Patients Acute and Chronic Bronchitis

Exclusion Criteria:

• Patients who have gotten a glucocorticoids treatment within 4 weeks.

• Patients who need treatments of antibiotic and acute bronchitis infection.

• Patients who have gotten teatments of antibiotic,bronchodilator,painkiller and secretagog within 7 days.

• Bronchial asthma patient.

• Patients who have an indication of bleeding.

• Patients who have a serious heart and renal disease or liver ailment or immunosuppressive response.

• Patients who have history of over 3 phage of Chronic obstructiv lung disease

• Bronchiectasis patients.